Q.01

What does the EU human medicines directive cover?

Directive 2001/83/EC, the Community code on medicinal products for human use, "shall apply to medicinal products for human use intended to be placed on the market in Member States and either prepared industrially or manufactured by a method involving an industrial process" (Article 2(1)). It covers the whole life of such a product: marketing authorisation, manufacture and import, labelling, legal classification, distribution, advertising, pharmacovigilance and enforcement. [1]

Approach: I read the current consolidated version of Directive 2001/83/EC (CELEX 02001L0083-20250101) as published in the Official Journal.

What counts as a "medicinal product" (Article 1)

  • Presentation limb: "any substance or combination of substances presented as having properties for treating or preventing disease in human beings."
  • Function limb: any substance or combination "which may be used in or administered to human beings" to restore, correct or modify physiological functions "by exerting a pharmacological, immunological or metabolic action," or to make a medical diagnosis. [2]

Article 1 also defines several product types: immunological products, ATMPs, homeopathic products, radiopharmaceuticals, products derived from human blood or plasma, and herbal and traditional herbal medicines. Falsified medicinal products are defined there too. [2][3]

Scope rules (Article 2)

  • Borderline products: where a product could meet both the medicinal product definition and the definition in other Community legislation, "the provisions of this Directive shall apply."
  • Manufacturing rules reach further: Title IV (manufacture) also applies to products made only for export, and to intermediate products, active substances and excipients.
  • Article 2(1) is "without prejudice to Articles 52b and 85a." [1]

Excluded (Article 3)

  1. Magistral formulae, meaning products a pharmacy prepares on prescription for one patient.
  2. Officinal formulae, meaning products a pharmacy prepares to a pharmacopoeia and supplies directly to its own patients.
  3. Products for research and development trials. This is without prejudice to Directive 2001/20/EC.
  4. Intermediate products for further processing by an authorised manufacturer.
  5. Radionuclides in sealed sources.
  6. Whole blood, plasma or blood cells of human origin. Plasma prepared by an industrial process is not excluded.
  7. Hospital-exemption ATMPs: prepared on a non-routine basis, used in a hospital in the same Member State, and made to an individual prescription for one patient. Their manufacture must still be authorised nationally. [4]

National carve-outs and things the Directive leaves alone (Articles 4-5)

  • Matters it does not affect:
    • EU radiation-protection rules.
    • Member States' powers on pricing and on health-insurance reimbursement.
    • National laws on contraceptives or abortifacients.
    • National laws on specific human or animal cell types. [5]
  • Optional national exclusions:
    • A Member State "may" exclude products supplied in response to a bona fide unsolicited order from an authorised healthcare professional, for one patient.
    • Member States "may" temporarily allow distribution of an unauthorised product in response to the suspected or confirmed spread of pathogenic agents, toxins, chemical agents or nuclear radiation. [6]

Core obligation (Article 6)

  • No medicinal product may be placed on a Member State's market without a marketing authorisation. That can be a national one under this Directive or a centralised one under Regulation (EC) No 726/2004.
  • The authorisation requirement also covers radionuclide generators, kits, radionuclide precursors and industrially prepared radiopharmaceuticals. [7]

Structure of the Directive

TitleSubject
IDefinitions [3]
IIScope [1]
IIIPlacing on the market [8]
IVManufacture and importation [9]
VLabelling and package leaflet [10]
VIClassification of medicinal products [11]
VIIWholesale distribution and brokering [12]
VIIIAdvertising [13]
IXPharmacovigilance [14]
XSpecial provisions for products derived from human blood and plasma [15]
XISupervision and sanctions [16]
XIIStanding Committee [17]
XIIIGeneral provisions [18]
XIVFinal provisions [19]

I can go into any Title in detail if useful, for example the authorisation routes in Title III or the GMP and import duties in Title IV.

Q.02

How will the EU pharmaceutical reform change it?

The reform repeals Directive 2001/83/EC and replaces it with a new Directive on the Union code relating to medicinal products for human use. It also repeals Directive 2009/35/EC. A companion Regulation replaces Regulation (EC) No 726/2004 and the orphan (141/2000) and paediatric (1901/2006) Regulations. The package is not yet law. The Council adopted its first-reading position on 28 September 2026. The Parliament's legislative tracker, last updated 25 October 2026, says the final plenary vote "could take place at the end of November 2026." 2001/83/EC is then repealed 24 months after the new Directive enters into force.

Approach: The datasets I can search hold 2001/83/EC and its amendments only up to 2023 and do not include the reform texts. So I read the Council's adopted first-reading text of the new Directive (ST 7106/2/26 REV 2), the Council's statements of reasons for the Directive and the Regulation, and the EU institutions' official pages.

Where it stands

DateStep
26 Apr 2023Commission proposals for a new Directive and a new Regulation
10 Apr 2024Parliament first-reading position
11 Dec 2025Provisional political agreement
6 Mar 2026Coreper confirms the compromise texts
18 Mar 2026Parliament's SANT committee approves them
28 Sep 2026Council adopts its first-reading position (Malta abstained)
PendingParliament second reading, then publication in the Official Journal

Sources: Council statement of reasons (Directive), Council minutes, 28-29 Sep 2026, EP Legislative Train.

Timing in the Council text (ST 7106/2/26 REV 2, Articles 220-223):

  • The Directive enters into force 20 days after publication.
  • Member States must transpose it and apply it within 24 months.
  • 2001/83/EC is repealed at that same 24-month point.
  • Transitional rules (Article 221):
    • Applications pending at that point are completed under 2001/83/EC.
    • Products already authorised come under the new Directive.
    • A reference product whose application was filed before the cut-off keeps the data protection periods of Article 10 of 2001/83/EC.
    • Products with old-format labelling may stay on the market until seven years after entry into force.

How scope changes compared with 2001/83/EC

Point2001/83/EC (current)New Directive (Council text)
ScopeProducts "prepared industrially or manufactured by a method involving an industrial process" (Art 2(1)) [1]Applies to medicinal products "intended to be placed on the market" (Art 1(2)). Art 1(1) lists placing on the market, manufacturing, import, export, supply, distribution, pharmacovigilance, advertising, supervision, control and use.
Borderline products"the provisions of this Directive shall apply"Where the rules conflict, "the rules set out in this Directive shall prevail" (Art 1(4))
ExclusionsMagistral and officinal formulae, R&D trial products, intermediates, sealed radionuclides, blood, hospital-exemption ATMPs (Art 3) [4]Magistral and officinal formulas (Art 1(5)). Investigational medicinal products under the Clinical Trials Regulation 536/2014, and substances of human origin (SoHO) unless they are ATMPs or SoHO-derived medicinal products (Art 1(6)).
Pharmacy preparationsNo advance preparation ruleMember States "may" let pharmacies prepare magistral formulas in advance, for up to 7 days or, when duly justified, up to 3 weeks, with records kept (Art 2(2))
Hospital exemption ATMPsExcluded, with national manufacturing authorisationSeparate Article 3: national approval notified to EMA, GMP-equivalent and pharmacovigilance requirements, at least annual data reporting, and an EMA data repository
National exemptionsUnsolicited-order supply; threats from pathogens, toxins, chemicals or radiationKept (Art 4(1), 4(4)). New: temporary national preparation to address shortages, withdrawals for non-safety reasons, or missing strengths or forms (Art 4(2)). Also new: products made only for the armed forces (Art 4(3)).

Main substantive changes

  • Regulatory protection: 8 years of data protection, with total protection capped at 11 years. Vouchers under the Regulation can take it to 12 years. A second year of market protection is available for a new active substance if it meets one of three pairs of criteria: comparative trials, trials in more than one Member State, and early EU filing. It is also available for products meeting an unmet medical need. (Council)
  • Supply obligations: Member States may require holders of the marketing authorisation to launch and supply innovative products. Requests can cover a pricing and reimbursement application, tender requirements or a roll-out plan. Market protection does not apply if the holder has not complied within three years of the request.
  • Bolar exemption: now extended to applications in procurement tenders.
  • Antimicrobials:
    • All antimicrobials become prescription-only. Member States may exempt topical products.
    • The package leaflet must open with the global AMR symbol.
    • A paper "awareness card" is required where leaflets are electronic only.
    • Applications must include an antimicrobial stewardship plan (Annex I, point 21).
  • Procedures:
    • Assessment of a marketing authorisation application is capped at 180 days.
    • Package leaflets become available electronically (Art 66, phased in under Art 221(9)).
    • Every application must include an environmental risk assessment under Articles 23-24 (Annex I, point 4).
    • Parliament also reports that authorisations become valid indefinitely by default, plus regulatory sandboxes and shortage prevention plans (EP press release).
  • Malta: Maltese authorisations based on former UK authorisations get extended validity (Art 221(11)).

What moves into the companion Regulation

These changes sit in the Regulation, not the Directive (Council statement of reasons, Regulation):

  • Orphan medicines: 11 years of market exclusivity for "breakthrough" orphan medicines and 9 years for other orphans.
  • Shortages: shortage prevention plans for prescription medicines. Supply disruptions must be notified "at least six months in advance."
  • Critical shortages: a Voluntary Solidarity Mechanism.
  • Antimicrobial voucher: a transferable data exclusivity voucher for priority antimicrobials, giving 12 months. It is subject to a €490 million annual-sales cap and limited to 15 years or 5 vouchers.
  • EMA committees: patient and healthcare professional representatives on CHMP and PRAC.

EMA expects the new framework to be fully applicable in 2028, with guidance issued during 2026-2028 (EMA). I can map any Title of 2001/83/EC to its new Chapter, for example labelling against Chapter VI, or GMP and import against Chapter XI.

Q.03